<DOC>
	<DOCNO>NCT01912612</DOCNO>
	<brief_summary>Early stage breast cancer typically treat surgery , chemotherapy , radiation therapy , and/or endocrine therapy . Following treatment , 25-60 % breast cancer survivor report chronic pain , difficult manage . Duloxetine serotonin norepinephrine reuptake inhibitor FDA approve treatment depression , anxiety , fibromyalgia , diabetic neuropathic pain , knee arthritis , low back pain . Pilot data suggest duloxetine effective management endocrine therapy-associated musculoskeletal pain , randomize placebo control trial duloxetine demonstrate efficacy treatment chemotherapy-induced neuropathic pain . In mechanistic study duloxetine versus placebo , investigate change pain sensitivity treatment order evaluate duloxetine effective management pain patient , well predictor likely benefit duloxetine . A total 84 woman early stage breast cancer chronic pain follow treatment , well 48 woman pain free , enrol . All subject undergo assessment pain sensitivity complete questionnaire . Subjects pain treated duloxetine total 7 week , pain sensitivity assessment treatment 4 week full-dose treatment .</brief_summary>
	<brief_title>Mechanistic Study Duloxetine Versus Placebo Breast Cancer Patients With Chronic Pain</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . Female patient least 25 year age 2 . Diagnosis stage 0III breast cancer within 12 year prior enrollment . All indicate surgery , chemotherapy , and/or radiation therapy must complete least 12 week prior enrollment . Concomitant endocrine therapy trastuzumab permit . 3 . Pain develop worsen since breast cancer diagnosis due identifiable traumatic event fracture 4 . Patientreported bad pain score 5 10 ( inclusive ) 010 scale ( assess verbally ) 5 . Female patient must least 1 year postmenopausal surgically sterile ; must agree use medically acceptable form contraception 6 . Willing withdraw selective serotonin reuptake inhibitor tricyclic antidepressant prior treatment initiation 7 . Patients currently take nonsteroidal antiinflammatory drug and/or opioid pain medication must remain stable dosage throughout duration study 8 . Able provide inform consent willing sign approve consent form conform federal institutional guideline . 1 . Prior use duloxetine milnacipran . 2 . Prior use venlafaxine specifically treatment pain ( prior use treatment indication , hot flash , permit ) 3 . Patients must take contraindicated medication list duloxetine package insert include follow : phenothiazine , propafenone , flecanide , linezolid , anticoagulation medication ( e.g. , heparin , warfarin ) ; treatment MAO inhibitor within 14 day prior registration . 4 . Thumbnail abnormalities either hand ( due chemotherapy trauma , artificial nail ) likely alter pain perception test 5 . Peripheral sensory neuropathy thumb bilaterally interfere function and/or activity daily live 6 . Significant risk suicide base Investigator 's judgment 7 . History behavior would , Investigator 's judgment , prohibit compliance duration study . 8 . History alcohol substance abuse dependence within year prior registration 9 . Known chronic liver disease , end stage renal disease , creatinine clearance &lt; 30 mL/min define CockcroftGault equation 10 . Uncontrolled narrowangle glaucoma . 11 . Clinically significant coagulation disorder 12 . History seizure disorder 13 . Pregnant breastfeeding . Urine pregnancy test assess baseline visit woman childbearing potential chronic pain . 14 . Unable take oral medication medical condition would interfere absorption study medication capsule . 15 . Currently take SSRI , SNRI , TCA regimen treatment major depressive disorder generalize anxiety disorder ( without approval involvement patient 's treating psychiatrist ) . Controls patient without chronic pain otherwise meet follow eligibility criterion ( inclusion # 1 , 2 , 8 , exclusion # 1 , 2 , 4 , 5 , worst pain score 01 , currently medication pain )</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Pain sensitivity</keyword>
</DOC>